Novavax Inc. has signed agreements to transfer one of its Maryland-based facilities and sell certain equipment, securing $60 million in cash payments. The transactions, including the assignment of a facility lease and sale of adjacent property, are expected to close between late 2025 and early 2026. Novavax anticipates future cash savings of $230 million over 11 years from reduced lease and operating costs, as part of its site consolidation and cost-reduction strategy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH03316) on October 22, 2025, and is solely responsible for the information contained therein.